A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

Active:	Yes
Cancer Type:	Solid Tumor Unknown Primary	NCT ID:	NCT05514717
Trial Phases:	Phase I	Protocol IDs:	MER-XMT-2056-1 (primary) NCI-2022-11090
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Mersana Therapeutics
NCI Full Details:	http://clinicaltrials.gov/show/NCT05514717

Summary

A Study of XMT-2056 in advanced/recurrent solid tumors that express HER2.

Objectives

The first-in-human (FIH) study of XMT-2056 is a Phase 1, open-label study of XMT-2056 in
previously treated patients with advanced/recurrent solid tumors expressing HER2. The
XMT-2056 monotherapy trial will consist of dose escalation (DES) and expansion (EXP)
parts.

DES will be the dose-finding portion of the study to assess the safety and tolerability
of XMT-2056 and determine the maximum tolerated dose (MTD) and/or Recommended Phase 2
Dose (RP2D). The RP2D will be determined based on the totality of the clinical data,
including safety and preliminary anti-tumor effect, PK, and relevant biomarker data.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.